aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
aspirin
RxCUI: 994239
What the CMS Formulary Data Shows for aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
Per the CMS 2026 Part D formulary file, aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] (RxNorm concept RXCUI 994239, generic name aspirin) appears on 15 distinct formulary files spanning 129 Medicare Part D plan offerings - 2.5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.7.
Real-world access to aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] depends on utilization management as much as tier placement: 33.3% of covering formularies require prior authorization. 0% require step therapy. 60% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 22,634 Part D beneficiaries filled aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] in 2023, with total plan-and-beneficiary spending of $31,146,709 and an average per-beneficiary annual cost of $1,376.10. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] today.
Coverage Details
- Formularies covering
- 15
- Plans covering
- 129
- Coverage rate
- 2.5%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 33.3% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 60% of formularies
2023 Medicare Spending
- Beneficiaries
- 22,634
- Total spending
- $31,146,709
- Avg per beneficiary
- $1,376.10
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] covered by Medicare Part D?
Yes, aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] is covered by 129 Medicare Part D plans (2.5% of all Part D formularies).
What tier is aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] on Medicare Part D plans?
aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] averages Tier 2.7 across Part D plans, ranging from Tier 1 to Tier 4.
Does aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] require prior authorization?
33.3% of Part D formularies require prior authorization for aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]. Step therapy: 0%. Quantity limits: 60%.
How much does Medicare spend on aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp]?
In 2023, total Medicare Part D spending on aspirin 325 MG / butalbital 50 MG / caffeine 40 MG / codeine phosphate 30 MG Oral Capsule [Ascomp] was $31,146,709, covering 22,634 beneficiaries. The average spend per beneficiary was $1,376.10.
Read our methodology - how this data is sourced, computed, and verified.